SCHEMBL24580937

SCHEMBL24580937

CCOC(=O)[C@H](C)[C@@H](C)c1ccc2c(c1)OCO2

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.52
RAB9A P51151 2/20 0.52
CYP1A2 P05177 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
NPC1 O15118 1/20 0.52
HTT P42858 1/20 0.52
OGA O60502 4/20 0.49
HPGD P15428 1/20 0.49
MME P08473 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
MAPT P10636 1/20 0.46
TSHR P16473 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12053329 0.86 CYP3A4 (0.55) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL6138702 0.84 RAB9A (0.56) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL8789026 0.83 RAB9A (0.55) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL7502509 0.82 RAB9A (0.53) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL7332440 0.82 CYP3A4 (0.53) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL24580941 0.81 PTGS1 (0.58) CYP3A4CYP1A2CYP2C9CYP2C19OGA
SCHEMBL6373806 0.80 RAB9A (0.51) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL6975784 0.80 RAB9A (0.51) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL5285048 0.78 CRHBP (0.52) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9
SCHEMBL8574095 0.78 CYP3A4 (0.50) CYP3A4RAB9ACYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022140464-A1 COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed